|
|||||
|
|
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody,plus irinotecan as second-line treatment for patients with metastatic colorectal cancer |
|
| Authors: | Johanna C. Bendell Heinz-Josef Lenz Theresa Ryan Bassel F. El-Rayes John L. Marshall Manuel R. Modiano Lowell L. Hart Clint D. Kingsley Thomas J. George Daisuke Nakashima Jordan D. Berlin |
| Affiliation: | 1. Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Suite 110, 250 25th Avenue North, Nashville, TN, 37203, USA 2. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA 3. Langone Medical Center, New York University, New York, NY, USA 4. Winship Cancer Institute, Emory University, Atlanta, GA, USA 5. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA 6. ACRC/Arizona Clinical Research Center and Arizona Oncology, Tucson, AZ, USA 7. Florida Cancer Specialists/Sarah Cannon Research Institute, Fort Myers, FL, USA 8. Clearview Cancer Institute, Huntsville, AL, USA 9. University of Florida, Gainesville, FL, USA 10. Kyowa Hakko Kirin Pharma, Inc., Princeton, NJ, USA 11. Vanderbilt-Ingram Cancer Center, Vanderbilt University, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN, 37232, USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |